What is Leap Therapeutics Cash Flow from Operations?
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Leap Therapeutics Cash Flow from Operations Historical Data
The historical data trend for Leap Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Leap Therapeutics's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics (NAS:LPTX) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Leap Therapeutics's net income from continuing operations for the
three
months ended in Mar. 2024 was $-13.82 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Leap Therapeutics's depreciation, depletion and amortization for the
three
months ended in Mar. 2024 was $0.01 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Leap Therapeutics's change in working capital for the
three
months ended in Mar. 2024 was $-3.07 Mil. It means Leap Therapeutics's working capital
declined by $3.07 Mil
from Dec. 2023 to Mar. 2024 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Leap Therapeutics's cash flow from deferred tax for the
three
months ended in Mar. 2024 was $0.00 Mil.
Leap Therapeutics's cash from discontinued operating Activities for the
three
months ended in Mar. 2024 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Leap Therapeutics's asset impairment charge for the
three
months ended in Mar. 2024 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Leap Therapeutics's stock based compensation for the
three
months ended in Mar. 2024 was $1.25 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Leap Therapeutics's cash flow from others for the
three
months ended in Mar. 2024 was $0.11 Mil.
Leap Therapeutics Cash Flow from Operations Related Terms
Thank you for viewing the detailed overview of Leap Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Leap Therapeutics (Leap Therapeutics) Business Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPTX has been successfully added to your 